What Pharma Supply Chain Leaders Should Be Asking at LogiPharma

LogiPharma is one of the few events in our industry where both the agenda and the hallway conversations are worth your full attention — and they tend to be valuable in different ways. The sessions bring structured perspective on where the industry is heading. The conversations between them surface what is actually happening inside facilities right now.

I am attending this year. The agenda is strong. What I find myself equally focused on are the questions that come up when practitioners compare notes between sessions — the ones that do not appear on any presentation slide, but that tend to reveal more about where an organization actually stands.

The Gap Between Compliance and Performance

Every pharmaceutical manufacturer knows what GDP compliance requires. The documentation, the temperature monitoring, the qualified transport lanes, the deviation management process. The regulations are not ambiguous. What remains genuinely difficult is the distance between meeting those requirements and running an operation that is also competitive.

The companies I have seen struggle most are not the ones that fail audits. They are the ones that built their supply chains almost entirely around avoiding audit failures — and then wonder why their logistics costs are high, their lead times are unpredictable, and their 3PL relationships feel like a constant renegotiation.

Compliance is the floor. Operational excellence is what you build above it. The two are not in tension — but you have to design for both from the start.

Three Questions Worth Asking in Every LogiPharma Conversation

1. How are you managing the tension between cold chain rigor and network flexibility?

Cold chain requirements constrain your network options. Temperature-controlled lanes, qualified warehouses, validated equipment — these reduce the number of partners you can work with. But supply chain disruption over the last few years has made network flexibility more valuable than ever.

The organizations handling this well are not trying to solve it through technology alone. They are investing in qualifying more partners upstream, building redundancy into their qualified supplier base, and treating cold chain validation as a competitive capability rather than a compliance checkbox.

That requires budget, relationships, and operational discipline. It is not solved by adding a monitoring dashboard.

2. When something goes wrong across your supply chain, who actually resolves it?

Pharmaceutical supply chains involve multiple parties — 3PLs, contract manufacturers, distributors, brand owners — each with their own systems, their own accountability boundaries, and their own definition of what counts as an exception.

When something goes wrong in transit — a temperature deviation, a shipment that does not scan correctly, a recall trigger — who resolves it? In many organizations, the honest answer is: it depends, and we work it out as it comes up.

That is an operational risk, not a technology problem. The track-and-trace infrastructure is largely in place. What remains inconsistent is the governance layer — who owns resolution, what the escalation path looks like, who has authority to make a decision about product that is currently on a truck.

The companies I have seen handle this well have defined those workflows before an incident required them to. They have tested them. They treat exception management not as emergency response, but as an operational capability that requires the same design attention as the systems that generate the exceptions in the first place.

3. What does your 3PL actually know about your product?

GDP compliance requires your third-party logistics provider to have a quality management system, trained personnel, and validated processes. But knowledge is different from compliance.

Two questions tend to reveal more about a 3PL relationship than any capability audit:

Where do you go outside of your system to get information you need?
What does exception management actually look like — who calls whom, what authority do they have, and how long does resolution take?

The organizations that have genuinely integrated their 3PL into their quality operations can answer both questions clearly. The ones that cannot tend to discover those gaps at the worst possible moment — during a deviation, a recall, or a regulatory inspection.

3PL selection in pharma tends to focus heavily on capability audits and cost. The organizations that get the most from their 3PL relationships invest in knowledge transfer — treating their logistics partner as an extension of their quality organization, not a vendor that handles the physical movement.

What Comes After the Conference

The value of LogiPharma is in both the sessions and the conversations they spark — and specifically in the ones that prompt you to reassess something you had stopped questioning.

If you come back with one genuinely useful observation — a different approach to exception management, a better framework for cold chain qualification, a new perspective on 3PL integration — and you act on it, the event has delivered a return.

If you come back with a stack of business cards and a general sense that others face the same challenges you do, it has been a pleasant trip but not a productive one.

The questions above are starting points. The answers depend on where your operation sits today — the maturity of your quality management system, the stability of your 3PL relationships, and the degree to which your supply chain has been designed for performance rather than just audit readiness.

If you want to talk through what those questions mean for your specific situation, we are happy to have that conversation. That is what practitioners do.

Learn more about SPARQ360’s pharma and life sciences logistics work, or explore our approach to supply chain optimization and technology implementation.